CRNX News and Press, Crinetics Pharmaceuticals Inc. From 06/04/24

2024-06-04 09:55:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-04 09:15:06 ET Oppenheimer analyst issues OUTPERFORM recommendation for CRNX on June 4, 2024 07:27AM ET. The previous analyst recommendation was Outperform. CRNX was trading at $46.28 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-06-04 09:00:05 ET Leland Gershell from Oppenheimer issued a price target of $74.00 for CRNX on 2024-06-04 07:27:00. The adjusted price target was set to $74.00. At the time of the announcement, CRNX was trading at $46.28. The overall price target consensus is at $67...

SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs. Dr. Cuddihy is a board-certified physician in endocrinology, diabetes and metabolism with more t...

2024-05-23 05:45:52 ET Summary Positive data released from 4 patients from phase 2 study that took Atumelnant for congenital adrenal hyperplasia, showing reductions in key biomarkers of A4 and 17-OHP. An NDA submission of Paltusotine for the treatment of patients with Acromegaly e...

2024-05-22 09:36:40 ET More on Crinetics Pharmaceuticals Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2024 Earnings Call Transcript Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade) Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2023 Earnings Ca...

SAN DIEGO, May 22, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that the la...

2024-05-15 10:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-11 10:09:07 ET Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Corey Davis - LifeSci Advisors Scott Struthers - Founder and Chief Executive Officer Alan Krasner - Chief Endocrinologist ...

SAN DIEGO, May 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 176,000 shares of its commo...